Table 1 Body weight and laboratory values measured over time in reported patient
From: How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
Day 1 On admission | Day 2 Before 1st TCZ dose | Day 3 Before 2nd TCZ dose | Day 3 After 2nd TCZ dose | Day 5 | Day 7 | Day 9 | Day 12 | Day 16 | Day 35 | |
|---|---|---|---|---|---|---|---|---|---|---|
Body weight (kg) | 86 | – | – | – | – | – | – | – | 77 | 79 |
SARS-CoV-2 RT-PCRa nasopharyngeal swab | Positive | – | – | – | – | Negative | Negative | – | – | Negative |
SARS-CoV-2 antibodiesb (AU/ml) | – | – | – | – | – | IgM 3.89 IgG 129 | – | – | – | IgM 2.05 IgG 63.77 |
IL-6 (pg/ml) | 177 | 298.9 | 1836 | 1479 | – | 98.2 | 86.2 | 42 | 28.3 | 37.1 |
CRP (mg/l) | 262 | 374 | 363 | 251 | 67 | 19 | 13 | 7 | < 5 | < 5 |
Ferritin (ng/ml) | – | 1615 | 5076.3 | – | – | 1454.3 | 1680.5 | 860.9 | – | 199.4 |
D-dimers (ng/ml) | 2007.15 | 2208.97 | 2336.06 | 2363.43 | 2821.55 | 2440.13 | 1587.5 | 564.19 | 249.43 | 110.14 |
Fibrinogen (g/l) | 8.26 | 7.37 | 4.54 | 4.15 | ||||||
Procalcitonin (ng/ml) | 1.12 | 1.00 | 1.56 | 1.39 | 1.12 | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
Leukocyte count (× 103/mm3) | 4.3 | 5.7 | 3.9 | 3.7 | 3.3 | 5.4 | 6.1 | 5.4 | 3.7 | 4.6 |
Neutrophile count (× 103/mm3) | 3.76 | 3.35 | 3.03 | 2.71 | 1.83 | 3.38 | 3.99 | 2.57 | 1.24 | 1.94 |
Platelet count (× 103/mm3) | 127 | 146 | 169 | 162 | 317 | 429 | 502 | 479 | 320 | 178 |
Hemoglobin (g/dl) | 13.7 | 12.1 | 11.8 | 12.2 | 13.6 | 13.5 | 12.8 | 13.4 | 13.2 | 12.9 |
ALT (U/l) | 74 | 61 | – | 50 | – | 304 | 236 | 209 | 180 | 124 |
AST (U/l) | 91 | 74 | – | 61 | – | 168 | 125 | 74 | 45 | 45 |
GGTP (U/l) | 137 | 165 | – | 141 | – | 547 | 514 | 336 | 214 | 96 |
Serum creatinine (mmol/l) | 83 | 81 | 53 | 42 | 110.9 | 134 | 125 | 81 | 114 | 86 |